知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.026 秒)

    Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
    1.
    发明授权
    Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling 有权

    公开(公告)号：US09719995B2

    公开(公告)日：2017-08-01

    申请号：US13800777

    申请日：2013-03-13

    申请人： NESTEC S.A.

    发明人： Phillip Kim ,  Sharat Singh

    IPC分类号： G01N33/574 ,  C12Q1/68

    CPC分类号： G01N33/57419 ,  G01N2333/71 ,  G01N2333/91205 ,  G01N2800/52

    摘要： The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene.

    PROFILING OF SIGNAL PATHWAY PROTEINS TO DETERMINE THERAPEUTIC EFFICACY
    4.
    发明申请
    PROFILING OF SIGNAL PATHWAY PROTEINS TO DETERMINE THERAPEUTIC EFFICACY 有权
    信号途径蛋白质的分析以确定治疗效果

    公开(公告)号：US20150017659A1

    公开(公告)日：2015-01-15

    申请号：US14194323

    申请日：2014-02-28

    申请人： Nestec S.A.

    发明人： Sharat Singh ,  Phillip Kim

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57492 ,  G01N33/5011 ,  G01N33/5041 ,  G01N33/542 ,  G01N2333/9121

    摘要： The present invention provides methods for detecting, measuring and quantitating the activation states of components of the PI3K signaling pathway in cells such as tumor cells. In particular embodiments, the present invention enable the determination of tumor adaptation to anticancer therapy. Accordingly, the present invention provides methods for improved cancer therapy selection/adjustment and disease monitoring.

    摘要翻译： 本发明提供了用于检测，测量和定量PI3K信号通路在诸如肿瘤细胞的细胞中的组分的激活状态的方法。 在具体实施方案中，本发明能够确定肿瘤适应抗癌疗法。 因此，本发明提供了改善癌症治疗选择/调整和疾病监测的方法。

    Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
    6.
    发明授权
    Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling 有权

    公开(公告)号：US10401364B2

    公开(公告)日：2019-09-03

    申请号：US15636534

    申请日：2017-06-28

    申请人： Nestec S.A.

    发明人： Phillip Kim ,  Sharat Singh

    IPC分类号： G01N33/574 ,  C12Q1/68

    摘要： The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy. The present invention further provides methods for the rational selection of therapy with one or more anticancer drugs tailored to target signal transduction pathway components with dysregulated expression and/or activation levels in patients with somatic mutations in an oncogene.

    METHOD OF THERAPY SELECTION FOR PATIENTS WITH CANCER
    9.
    发明申请
    METHOD OF THERAPY SELECTION FOR PATIENTS WITH CANCER 审中-公开
    癌症患者治疗方法选择

    公开(公告)号：US20140273006A1

    公开(公告)日：2014-09-18

    申请号：US14294449

    申请日：2014-06-03

    申请人： NESTEC S.A.

    发明人： Sharat Singh ,  Anne Kuller ,  Tani Ann T. Lee ,  Saswati Hazrar ,  Richard Kirkland ,  Xinjun Liu ,  Phillip Kim

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57484 ,  G01N33/542 ,  G01N33/57488 ,  G01N33/57492 ,  G01N2800/52

    摘要： The present invention provides methods for detecting, measuring and quantitating the expression and activation states of signal transduction analytes in cells such as tumor cells. The invention also provides methods for selecting therapy, optimizing therapy, monitoring therapeutic efficacy, and/or detecting therapeutic resistance. Accordingly, the methods are useful for improving cancer therapy selection and disease monitoring.

    摘要翻译： 本发明提供了用于检测，测量和定量细胞如肿瘤细胞中信号转导分析物的表达和激活状态的方法。 本发明还提供了选择治疗，优化治疗，监测治疗功效和/或检测治疗抵抗力的方法。 因此，该方法可用于改善癌症治疗选择和疾病监测。

    METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS
    10.
    发明申请
    METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF GASTRIC CANCER PATIENTS 审中-公开
    预防和改善胃癌患者存活的方法

    公开(公告)号：US20140099300A1

    公开(公告)日：2014-04-10

    申请号：US14044792

    申请日：2013-10-02

    申请人： NESTEC S.A.

    发明人： Phillip Kim ,  Sharat Singh

    IPC分类号： G01N33/68 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/517

    CPC分类号： G01N33/6893 ,  A61K31/517 ,  A61K31/5377 ,  A61K45/06 ,  G01N33/57446 ,  G01N2333/71 ,  G01N2800/52 ,  G01N2800/54 ,  G01N2800/56

    摘要： The present invention provides assays and methods for predicting the post-operative survival of a subject having an early stage gastric cancer after tumor surgery. The present invention also provides methods for treating a subject having an early stage gastric cancer by administering a combination therapy tailored to the signal transduction biomarkers that are activated in the cancer. In particular embodiments, the methods of the invention rely on the detection of the activation state or level of a specific combination of signal transducer analytes in a cancer cell obtained from the subject. Thus, the methods of the invention are particularly useful for predicting the survival or prognosis of a subject having an early stage gastric cancer and for guiding both pre- and post-operative treatment decisions by identifying subjects who would benefit from combination therapy as opposed to monotherapy.

    摘要翻译： 本发明提供了用于预测肿瘤手术后具有早期胃癌的受试者的术后存活的测定和方法。 本发明还提供了通过施用针对在癌症中被激活的信号转导生物标志物进行定制的组合疗法来治疗患有早期胃癌的受试者的方法。 在具体实施方案中，本发明的方法依赖于从受试者获得的癌细胞中检测信号转导分析物的特定组合的活化状态或水平。 因此，本发明的方法对于预测具有早期胃癌的受试者的存活或预后特别有用，并且通过鉴定受益于组合治疗的受试者而不是单一疗法来指导术前和术后治疗决定 。